Celsius Therapeutics (SCOPE Platform)

Celsius Therapeutics leverages its proprietary SCOPE (Single-cell Multi-omics Precision Engine) platform to redefine drug discovery for complex immune-mediated diseases and oncology. By integrating high-resolution single-cell RNA sequencing (scRNA-seq) with advanced machine learning algorithms, the platform identifies the specific cellular drivers of disease within complex tissue ecosystems. Unlike traditional bulk sequencing, which averages signals across different cell types, Celsius's architecture maintains the granular resolution of individual cells, allowing for the identification of rare cell populations and specific gene expression pathways that drive pathology. By 2026, the platform has matured into a benchmark for patient stratification, enabling the discovery of first-in-class therapeutic targets and biomarkers that predict patient response with high fidelity. The technical stack combines cloud-based bioinformatics pipelines, deep learning models for cell-state transition mapping, and longitudinal clinical data integration to transform observational biology into actionable therapeutic programs. This approach positions Celsius as a critical partner for major pharmaceutical entities looking to de-risk clinical development through molecularly defined patient cohorts.